TFS forms partnership to conduct a global RWE study on Covid-19 pandemic.

TFS joins Observational Health Data Sciences and Informatics (OHDSI) community in a COVID-19 virtual
study-a-thon (March 26-29) to inform healthcare decision-making in response to the current global
pandemic. With the increasing availability of real-world COVID-19 data worldwide the main purpose of
the event is to generate immediate real-world evidence on prioritized questions shared by national
governments, public health agencies, health-related institutions, and community members; and to
design COVID-19-specific studies that can be validated and available to run when such data is available.
(source: ohdsi.org)

TFS partners with IOMED on a recently approved local RWE study, “COVID-19 REAL”. Within this strategic
partnership, TFS will analyze data using the standardized tools provided by the OHDSI collaboration. The
COVID-19 REAL focuses on helping address current gaps in the management of COVID-19 pandemic. It is
a non-interventional, retrospective, database, cohort study based on anonymized and routinelycollected
health care data from several Spanish Hospitals. All generated real-world evidence will be
placed in the public domain to support and inform current public health efforts. Patient privacy will be
protected in all studies.

Coronavirus disease 2019 (COVID-19) pandemic has an urgent need for answering many questions
regarding epidemiology and natural history of the disease. Neus Valveny, TFS Operational Strategy Lead
Real World Evidence, addresses the importance of real world evidence to complement clinical trial
results. “Similarities and differences with other viral infections as well as effectiveness and safety of
current preventive or therapeutic measures are extremely important. Models assessing most relevant
prognostic factors in the daily practice will be also crucial to help healthcare providers decide which
subjects should be prioritized and given more intensive therapies. The full analysis needs to be adjusted
for potential confounding and biases inherent to observational research”

About TFS

TFS was founded in 1996 and has grown to become the leading global mid-size clinical CRO focusing on small and mid-size
Biotech customers. TFS employs nearly 700 professionals throughout 21 countries and currently delivers clinical research
services in more than 40 countries. We provide end-to-end solutions including full clinical development services, strategic
resourcing and flexible single services. Our partnering approach with customers is based on our four business principles –
commitment, flexibility, value creation and global reach. Our core therapeutic specialties are Dermatology, Hematology and
Oncology, Ophthalmology as well as Internal Medicine and Neurology
Detailed information about TFS, and its business offerings can be obtained through www.tfscro.com

For further information, please contact:

Sylwia Domagalska

Director Marketing and Corporate Communications

Email: sylwia.domagalska@tfscro.com

Phone: +48 787 913 074

Tags: